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Summary
Simpson-Golabi-Behmel syndrome (SGBS) is an X-
linked overgrowth syndrome with associated visceral
and skeletal abnormalities. Alterations in the glypi-
can-3 gene (GPC3), which is located on Xq26, have
been implicated in the etiology of relatively milder
cases of this disorder. Not all individuals with SGBS
have demonstrated disruptions of the GPC3 locus,
which raises the possibility that other loci on the X
chromosome could be responsible for some cases of
this syndrome. We have previously described a large
family with a severe form of SGBS that is character-
ized by multiple anomalies, hydrops fetalis, and death
within the first 8 wk of life. Using 25 simple tandem-
repeat polymorphism markers spanning the X chro-
mosome, we have localized the gene for this disorder
to an ∼6-Mb region of Xp22, with a maximum LOD
score of 3.31 and with LOD scores !52.0 for all of
Xq. These results demonstrate that neither the GPC3
gene nor other genes on Xq26 are responsible for all
cases of SGBS and that a second SGBS locus resides
on Xp22.
Introduction
Simpson-Golabi-Behmel syndrome (SGBS; MIM
312870) is an X-linked disorder characterized by pre-
and postnatal macrosomia, minor facial anomalies,
and variable visceral, skeletal, and neurological ab-
normalities. Since SGBS was first described by Simp-
son et al. (1975), a wide range of clinical presentations
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has been reported. There is great variability in SGBS
severity, which ranges from a mild form that is as-
sociated with long-term survival to an early lethal
form that is associated with multiple congenital anom-
alies and severe mental retardation. In eight reported
families, affected individuals died in infancy. We have
previously described a family in which four maternally
related male cousins had a severe form of SGBS (Ter-
espolsky et al. 1995). One of these males was vol-
untarily aborted at 19 wk gestation, after multicystic
kidneys were detected on ultrasound. The three live-
born males were hydropic at birth and had a com-
bination of craniofacial anomalies, including macro-
cephaly; apparently low-set, posteriorly angulated
ears; hypertelorism; a short, broad nose with antev-
erted nares; a large mouth with a thin, vermilion up-
per border; a prominent philtrum; a high-arched or
cleft palate; a short neck; redundant skin; hypoplastic
nails; skeletal defects involving the upper and lower
limbs; and gastrointestinal and genitourinary anom-
alies. All three patients were hypotonic and neurol-
ogically impaired from birth. With the exception of a
trilobate left lung in one patient, the cardiorespiratory
system was structurally normal. All patients died of
multiple complications, including pneumonia and sep-
sis, within the first 8 wk of life.
SGBS has been mapped to the long arm of the X
chromosome in a number of kindreds with moderate
expression of the condition (Hughes-Benzie et al. 1992;
Ireland et al. 1993; Orth et al. 1994; Xuan et al. 1994).
In 1996, Pilia et al. identified, in two female patients
with X/autosome translocations, disruptions in the
GPC3 locus, on Xq26, which codes for the extracellular
proteoglycan glypican-3 (GPC3). Microdeletions in
GPC3 were also found to cosegregate with SGBS in three
families (Pilia et al. 1996), althoughGPC3 deletions have
not been subsequently detected in all cases of SGBS
(Lindsay et al. 1997). Using a single four-generation fam-
ily segregating an infantile lethal form of SGBS, we have
mapped, to chromosome Xp22, a second SGBS locus,
which is well removed from the GPC3 locus on Xq26.
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Figure 1 Pedigree of a family with an infantile lethal variant of
SGBS, with genotypes of markers from Xp22. Affected individuals are
denoted by a blackened symbol. Obligate carrier females are desig-
nated by a black dot within an unblackened circle. The haplotype
segregating with SGBS is boxed. Flanking recombinants occur between
the loci DXS7104 and DXS16 in individuals III-2 and III-4 and be-
tween the loci DXS1195 and DXS8019 in individual III-7.
Subject and Methods
Subjects
The subjects in the present study are from a four-
generation family with four male cousins affected with
an infantile lethal form of SGBS (fig. 1). Informed con-
sent was obtained from all participants, and all study
procedures were approved by the ethics committees of
the University of Toronto, The Hospital for Sick Chil-
dren, and Rutgers University. The 15 unaffected mem-
bers who participated were generally unremarkable phe-
notypically, with the exception of striking hypertelorism
in the carrier females. The clinical features of the four
affected males have been described in detail elsewhere
(Terespolsky et al. 1995).
Genotyping
DNA was extracted, by standard techniques, from pe-
ripheral blood leukocytes, except in the case of family
member IV-3, whose DNA was extracted from brain
tissue stored in liquid nitrogen. DNA from each subject
was genotyped by use of 13 X-chromosome markers
(DXS989, DXS1068, DXS6810, DXS1003, DXS7132,
DXS6800, DXS6789, DXS6799, DXS6797, DXS6804,
DXS1001, DXS1047, and GATA31E08) from theWeber
version 6.0 Screening Set as well as 12 additional chro-
mosome-Xp markers (DXS1060, DXS1223, DXS8051,
DXS7104, DXS16, DXS8022, DXS207, DXS1053,
DXS43, DXS1195, DXS8019, and DXS7107), all ob-
tained from Research Genetics. PCR amplificationswere
performed in a reaction volume of 12 ml containing 40
ng template DNA; 0.2 mM each of dATP, dGTP, and
dTTP; 1.25 mmol dCTP; 25 nM [32P]a-dCTP; 12 pmol
each primer; 50 mM KCl; 10 mM Tris-HCl (pH 8.3);
1.9–2.5 mM MgCl2; and 0.12 U AmpliTaq Gold DNA
polymerase (Perkin-Elmer). Thermocycling was con-
ducted by means of an MJ Research PTC-100 thermo-
cycler, with an initial denaturation step of 15 min at
95oC; then 10 cycles of 15 s at 95oC, 15 s at 55oC, and
15 s at 72oC; an additional 15–20 cycles of 15 s at 89oC,
15 s at 55oC, and 15 s at 72oC; and a final extension
step of 10 min at 72oC. PCR products were analyzed by
electrophoresis on 6% nondenaturing acrylamide gels,
and subsequent autoradiography was done at room tem-
perature with Dupont Reflections film.
Linkage Analysis
Two-point linkage analyses were performed by use of
the MLINK program of the LINKAGE package, version
5.1 (Lathrop et al. 1984), and multipoint analyses were
conducted by use of the LINKMAP program of the FAS-
TLINK package, version 4.0P (Cottingham et al. 1993;
Scha¨ffer et al. 1994). All analyses were conducted by
use of an X-linked model, with a disease-allele frequency
of .0001 and penetrances of 1.0 for disease-allele hem-
izygotes and homozygotes and with penetrances of .0
for all other genotypes. All 25 markers were used in the
two-point analyses. Multipoint analyses were conducted
by use of a set of 23 markers. Marker order and recom-
bination fractions for 10 Xp markers distal to DXS989
were taken from the Ge´ne´thon genetic map (Dib et al.
1996), and the remaining markers and recombination
fractions were taken from the map provided with the
Weber version 6.0 Screening Set. The two maps were
joined at marker DXS989, which is present in both
maps. The final map used was as follows: DXS1060-
.036-DXS1223-.020-DXS8051-.037-DXS7104-.047-
DXS8022-.015-DXS1053-.026-DXS1195-.001-
DXS8019-.036-DXS7101-.049-DXS1052-.070-
DXS989-.160-DXS1068-.060-DXS6810-.130-
DXS1003-.090-DXS7132-.100-DXS6800-.140-
DXS6789-.050-DXS6799-.060-DXS6797-.060-
Brzustowicz et al.: Mapping of SGBS to Xp22 781
Figure 2 Multipoint linkage analysis of SGBS and X-chromo-
some markers. The order of the markers is DXS1060, DXS1223,
DXS8051, DXS7104, DXS8022, DXS1053, DXS1195, DXS8019,
DXS7101, DXS1052, DXS989, DXS1068, DXS6810, DXS1003,
DXS7132, DXS6800, DXS6789, DXS6799, DXS6797, DXS6804,
DXS1001, DXS1047, and GATA31E08. For orientation, the positions
of the italicized markers are plotted as unblackened symbols on the
X-axis, and their names are listed on the figure. The remainder of the
single marker positions are plotted as blackened diamonds. Because
of their proximity, DXS1195 and DXS8019 appear together and are
plotted as an unblackened square. The locus GPC3 was not used in
the multipoint analysis, but it is plotted for reference.
Table 1
Pairwise LOD Score with Chromosome-X Markers
LOD SCORE AT v =
LOCUS .0 .01 .05 .1 .2 .3 .4
DXS1060  .73 .49 .85 .95 .75 .41
DXS1223  .73 .49 .85 .95 .75 .41
DXS8051  1.47 .18 .29 .57 .55 .35
DXS7104  1.63 .37 .05 .27 .23 .11
DXS16 3.31 3.26 3.04 2.76 2.16 1.49 .76
DXS8022 2.71 2.67 2.49 2.25 1.75 1.19 .06
DXS207 3.31 3.26 3.04 2.76 2.16 1.49 .76
DXS1053 3.01 2.96 2.74 2.47 1.89 1.28 .66
DXS43 3.01 2.96 2.74 2.47 1.88 1.26 .62
DXS1195 1.69 1.67 1.57 1.45 1.17 .84 .45
DXS8019  1.26 1.77 1.81 1.55 1.12 .59
DXS7101  .33 .3 .5 .57 .47 .28
DXS989  1.26 1.77 1.81 1.55 1.12 .59
DXS1068  3.95 1.92 1.11 .4 .09 .02
DXS6810  .81 .16 .07 .21 .22 .14
DXS1003  5.33 2.62 1.53 .58 .16 .01
DXS7132  10.71 5.88 3.87 1.97 .97 .36
DXS6800  3.19 1.8 1.2 .62 .31 .12
DXS6789  6.05 3.39 2.35 1.38 .78 .32
DXS6799  5.91 3.16 2.03 .98 .45 .15
DXS6797  5.93 3.18 2.04 .99 .45 .15
DXS6804  3.61 1.61 .82 .17 .07 .11
DXS1001  6.71 3.33 1.96 .76 .23 .01
DXS1047  10.71 5.88 3.87 1.97 .97 .36
GATA31E08  3.91 1.88 1.08 .38 .08 .03
DXS6804-.140-DXS1001-.120-DXS1047-.110-
GATA31E08. Overlapping sets of five-point analyses
were conducted and assembled to produce the chro-
mosome-wide multipoint analysis. Recombination frac-
tions (v) were converted to map distances by use of the
Kosambi mapping function. Haplotypes were assembled
for markers from Xp22, according to the physical order
in the map constructed by Ferrero et al. (1995). This
map was also used to estimate the physical distances
between these markers.
Results
Two-point analyses produced predominantly negative
results throughout the length of the X chromosome,with
the exception of the markers centered around Xp22 (ta-
ble 1). With markers DXS16 and DXS207, the maxi-
mum two-point LOD score was 3.31 at v = 0; four ad-
ditional markers from Xp produced somewhat lower
maximum LOD scores at v = 0. The maximum multi-
point LOD score was 3.31 for the entire 4.1-cM region
from DXS8022 to DXS1195 (fig. 2), with a 1-LOD-unit
support interval spanning the 9-cM region from
DXS7104 to DXS8019. Multipoint analysis produced
LOD scores !2.0 for the region of Xp distal to
DXS7104 and proximal to DXS1068, as well as for all
of Xq, including the region containing the GPC3 locus.
Haplotypes constructed from 10 Xp markers revealed
flanking recombination events between the adjacent
markers DXS7104 and DXS16 and between adjacent
markers DXS1195 and DXS8019 (fig. 1). This confines
the linked locus to a region of ∼5.7–6.5 Mb on chro-
mosome Xp22.
Discussion
We have used linkage analysis to map to Xp22 a
second locus for SGBS, a locus that is clearly distinct
from the GPC3 gene on Xq26. Cases of SGBS that
are as severe as those seen in the family reported in
the present study are rare, and we are unaware of any
similar families that are available for linkage analysis.
Despite the small size of this family, we were able to
obtain a significant LOD score of 3.31 and to define
a candidate region of ∼6 cM between markers
DXS8022 and DXS1195. The candidate region can-
not be narrowed further, since, in this family, there
are no other informative polymorphic markers that
map to this region.
The finding, in this family, of a new locus for SGBS
adds an additional gene to the constellation of players
acting in the molecular pathway of SGBS. The pheno-
typic overlap between SGBS and the related overgrowth
disorder Beckwith-Wiedemann syndrome (BWS) has
previously suggested that there is a final, common met-
abolic pathway for these two conditions. For BWS, ge-
netic heterogeneity is already well documented, in that
the genes for insulin-like growth factor 2 (IGF2), the
cyclin-dependent kinase inhibitor p57KIP2, the untran-
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slated transcript H19, and the potassium-channel com-
ponent KVLQT1 have all been implicated (Li et al.
1998). Increased activity of IGF2 appears to play a cen-
tral role in the development of the BWS phenotype, and
it is hypothesized that other genes achieve their effects
through modulation of IGF2 expression or function. A
similar role has been proposed for GPC3, and this idea
is supported by data from mouse experiments in which
targeted deletions of p57KIP2 or GPC3 and overexpres-
sion of IGF2 produce phenotypes overlapping both BWS
and SGBS (Li et al. 1998).
There are still a number of etiologic and nosological
issues to be resolved with respect to SGBS. The wide
clinical variation among cases of SGBS has resulted in
extensive discussion about possible genetic heterogeneity
(Opitz 1984; Opitz et al. 1988; Neri et al. 1998). To
date, only translocations or deletions in the GPC3 gene
have been described. However, in studies of individuals
with SGBS who have normal karyotypes, only 30% of
these individuals have deletions in GPC3 (Lindsay et al.
1997). Other types of mutations have not yet been iden-
tified in this gene, even within families in which SGBS
is linked to a locus at Xq26. DNA sequencing may even-
tually identify point mutations in GPC3 in these patients.
Although the glypican-4 (GPC4) gene, which is located
adjacent to the GPC3 gene on Xq26, could also be a
candidate for SGBS, all deletions of GPC4 that have been
reported to date also involve GPC3 (Huber et al. 1998;
Veugelers et al. 1998).
For some families and individuals with less severe
forms of SGBS, it is possible that causative mutations
are present in this new, Xp22 locus for SGBS. Further
data will be needed to determine whether this is true or
whether all Xp22-associated cases of SGBS will exhibit
a severe phenotype, which would suggest that the dis-
order caused by the Xp22 locus should be classified as
a distinct genetic disorder. Final resolution of this di-
lemma will have to be deferred until the SGBS gene at
Xp22 is identified and until mutations can be defined in
the relevant candidate genes on Xp22 and Xq26, for a
full spectrum of patients with SGBS.
The SGBS region identified in the present study con-
tains no known genes that can be obviously implicated
in the etiology of SGBS. The region is known to contain
the genes for phosphoribosyl pyrophosphate synthetase-
2, the neuronal membrane glycoprotein M6B, the a-2
subunit of the glycine receptor, phosphatidylinositol gly-
can class A, the nonreceptor tyrosine kinase BMX, the
gastrin-releasing peptide receptor, the U2 small-nuclear
ribonucleoprotein auxiliary factor small subunit 2, and
the vitamin D–dependent calcium-binding protein cal-
bindin3 (Ferrero et al. 1995). In addition, sequences are
present that have high homology to the murine genes
for ubiquitin-conjugating enzyme UbcM3 and clatharin
coat-assembly protein AP19, as well as to the human
genes for SET (suppressor of variegation, enhancer of
zeste and Trithorax) protein, CTP (cytidine 5′-triphos-
phate) synthetase, and ribosomal protein L6. It is of
interest that the genes of known function in this region
include such signaling molecules as BMX and the re-
ceptor for the growth-factor gastrin-releasing peptide.
There is no indication that any of these genes represent
a good candidate gene for this second SGBS locus. How-
ever, since the candidate region of 6 Mb is expected to
contain 1100 genes, it is not surprising that the small
percentage of genes identified in this area to date do not
contain a likely candidate.
The linkage of SGBS to Xp22 will facilitate the po-
sitional cloning of this gene. Ultimately, identification of
a second SGBS gene will lead to the elucidation of its
biological role and will contribute to our understanding
of the genes that underlie human overgrowth syndromes.
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